Skip to content
Menu

Bone Biologics Corporation BBLG

Full chart Compare
Set alert

Price alert · BBLG

All alert types
0.27 USD -0.01 (-2.40%)

Regular-session close

0.27 0.00 0.00%

After hours · Nov 20, 4:27 PM ET

0.2679 Day range 0.285
0.2685 52-week range 2.11
YTD
-81.48%
1 year
-81.09%

5D -0.1169 (-29.82%)

0.30000.35000.4000FriMonTueWedThu0.2751
Market cap
909.96K
EPS (ttm)
-0.96
Shares out
2.46M
Forward P/E
-0.41
YTD return
-81.48%
1-year return
-81.09%
50-day average
1.34
200-day average
1.60
Volume
36.49K
Avg volume
255.29K
Open
0.276
Previous close
0.2751
Day's range
0.2679 – 0.285
52-week range
0.2685 – 2.11
Beta
0.74
Price target
16.75 (+6138.4%)

Key statistics

Enterprise value
-188.37K
Price / book
0.17
Free cash flow
-4.83M
Total cash
2.33M
Return on equity
-119.03%
Short % of float
3.49%

Fundamental scorecard

7 of 25 checks passed on BBLG’s reported financials

ValueGrowthProfitabilityHealthDividend

7of 25 checks passed

  • Value 1 of 5
  • Growth 1 of 5
  • Profitability 0 of 5
  • Financial health 5 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
BBLG Revenue — quarterly 0
BBLG Net income — quarterly -617.65K
BBLG EPS — quarterly -0.17

Earnings

BBLG recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 14, 2024Sep 1, 2024-0.60-2.37-1.77-295.00%
Aug 9, 2024Jun 1, 2024-1.39-0.67+0.72+51.80%
Aug 9, 2024Jun 1, 2024-1.39———
May 14, 2024Mar 1, 2024-7.60———
May 14, 2024Mar 1, 2024-7.60-1.31+6.29+82.76%
Apr 4, 2024Dec 1, 2023-5.56———

About Bone Biologics Corporation

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1. The company's platform technology is used in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.

Sector
Healthcare
Industry
Medical Devices
Country
United States

News

Your note

Sign in to keep a note on BBLG — it syncs with the Stock Master app.

Insider holders

BBLG insider holders
InsiderRelationLatest transactionDateShares held
FRELICK JEFFREYChief Executive OfficerPurchaseSep 10, 202317,204
WALSH DEINA HChief Financial OfficerPurchaseSep 12, 202315,000

Institution ownership

BBLG institution ownership
Holder% heldSharesValueReported
UBS Group AG1.32%32,85129.57KSep 29, 2024
Morgan Stanley1.14%28,52725.68KSep 29, 2024
HRT Financial LP0.89%22,27620.05KSep 29, 2024
Tower Research Capital LLC (TRC)0.07%1,7861.61KSep 29, 2024
CWM, LLC0.02%444399Sep 29, 2024
MFA Wealth Advisors, LLC0.02%403362Sep 29, 2024

Fund ownership

BBLG fund ownership
Holder% heldSharesValueReported
Fidelity Extended Market Index Fund0.36%8,9108.02KOct 30, 2024
Fidelity Total Market Index Fund0.16%3,9363.54KOct 30, 2024
Fidelity Series Total Market Index Fund0.11%2,7472.47KOct 30, 2024